EXPERIENCE OF NIFURATEL USAGE IN COMPLEX TREATMENT OF CHRONIC SPECIFIC BACTERIAL FIBROUSE AND CALCULOUS PROSTATITIS ASSOCIATED WITH TRICHOMONIASIS AND CANDIDOSIS
The aim of the study was to analyze the effi cacy of the drug “Macmiror” (active substance – nifuratel) in the treatment of chronic specifi c bacterial fi brous and calculous prostatitis associated with trichomoniasis and candidiasis.
Materials and methods. The study was conducted on 50 patients of the “Clinic “Men’s Health”, suff ering from chronic specifi c bacterial fi brous and calculous prostatitis (mixed infection: trichomonadial-bacterial-candidiasis associates of various structure). As methods of research, in addition to the standard complex, the following were chosen: IN POUCH TV-test; PCR method; sonographic examination of
the prostate and spermogram.
Results of the study. Patients who completed the study were treated with chronic specifi c bacterial fi brous and calculous prostatitis (N41.1) for 14 days, according to the following therapeutic model: oral administration of nifuratel as part of the “Macmiror” preparation at a total dosage of 1200 mg per day (6 tablets of 200 mg) divided into 3 doses and physiotherapy.
Conclusions. A general (in relation to diff erent types and combinations of infectious agents) of the therapeutic model has been established at a level of 71% to 100%. Treatment had absolute (clinical and laboratory) effi cacy against isolated Candida spp.; absolute clinical effi cacy and 71-85% laboratory effi cacy against isolated Trichomonas vaginalis; 92% clinical and 76-84% laboratory effi cacy against the combination of these infectious agents; 92% clinical and 80% laboratory effi cacy against the combination of these infectious agents and non-specifi c bacterial fl ora, as the etiological factors of chronic specifi c bacterial prostatitis.
2. Горпинченко І. І., Литвинець Є. А., Сандурський О. П. та ін. Діагностика хронічного простатиту: сучасні реалії та проблеми // Здоровье мужчины. 2014. № 1. С. 105–110.
3. Krieger JN, Ross SO, Limaye AP, Riley DE. Inconsistent localization of gram-positive bacteria to prostate-specifi c specimens from patients
with chronic prostatitis. Urology. 2005 Oct. 66 (4):721-5.
4. Nickel JC, Costerton JW, McLean RJ, Olson M. Bacterial biofi lms: infl uence on the pathogenesis, diagnosis and treatment of urinary tract
infections. J Antimicrob Chemother. 1994 May. 33 Suppl A:31-41
5. Pontari MA. Etiology of chronic prostatitis/chronic pelvic pain syndrome: psychoimmunoneurendocrine dysfunction (PINE syndrome) or just a really bad infection?. World J Urol. 2013 Apr 12.
6. Wiygul RD. Prostatitis: epidemiology of infl ammation. Curr Urol Rep. 2005 Jul. 6(4):282-9.
7. Magri V, Perletti G, Montanari E, Marras E, Chiaff arino F, Parazzini F. Chronic prostatitis and erectile dysfunction: results from a crosssectional
study. Arch Ital Urol Androl. 2008 Dec. 80(4):172-5.
8. Bisschop M.P. et al. Co-treatment of the male partner in vaginal candidosis: a doble-blind randomized control study. British Jornal of Obstetrics and Gynaecology 1986, 93 (1): 79-81.
9. Ford I.W. et al. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole// Genitourin-
Med.1992; 68 (3):174-176.
This work is licensed under a Creative Commons Attribution 4.0 International License.